Defining success in neoadjuvant breast cancer trials

Affiliations

¹ University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA. Electronic address: lisa_carey@med.unc.edu.
² Dana-Farber Cancer Institute, Boston, MA, USA.

Comment

Lisa A Carey et al. Lancet. 2014.

. 2014 Jul 12;384(9938):115-6.

doi: 10.1016/S0140-6736(14)60034-9. Epub 2014 Feb 14.

¹ University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA. Electronic address: lisa_carey@med.unc.edu.
² Dana-Farber Cancer Institute, Boston, MA, USA.

No abstract available

Comment on

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Cortazar P, et al. Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Lancet. 2014. PMID: 24529560 Review.